Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulleyaconitine A tablets for chronic musculoskeletal pain
ChiCTR2500097021Phase 4Not yet recruiting
- Sponsor
- Third Affiliated Hospital, Beijing University of Chinese Medicine
- Start
- Feb 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bulleyaconitine a and duloxetine in chronic musculoskeletal pain and chronic low back pain (CLBP) (2 arms), sponsored by Third Affiliated Hospital, Beijing University of Chinese Medicine. Primary endpoint: VAS score. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
bulleyaconitine aduloxetine
03
Conditions
chronic musculoskeletal painchronic low back pain (CLBP)
Beyond the preview
Go deeper on ChiCTR2500097021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097021.